Actelion to discuss US FDA approval of Uptravi (selexipag) for the treatment of pulmonary arterial hypertension
ID: 1302814
Actelion Pharmaceuticals Ltd /
Actelion to discuss US FDA approval of Uptravi (selexipag) for the treatment of
pulmonary arterial hypertension
. Verarbeitet und übermittelt durch NASDAQ OMX Corporate Solutions.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Source: Globenewswire
Dear member of the investment community
Actelion announced today that the United States Food and Drug Administration
(FDA) has approved the use of the orally active, selective IP prostacyclin
receptor agonist Uptravi (selexipag) for the treatment of pulmonary arterial
hypertension (PAH).
An investor conference call & webcast will be held to discuss the approval at
14:00hrs on 05 January 2016.
Date/Time:
05 January 2016 14:00hrs - 15:00hrs Basel (CET)
13:00hrs - 14:00hrs UK (GMT)
8:00 a.m. - 9:00 a.m. US (EST)
Conference Call and Webcast
Participants will find dial-in information and a link to the webcast on the
Actelion website www.actelion.com at least 24hrs ahead of when the conference is
due to start.
Webcast Replay:
The archived Investor Webcast will be available for replay through
www.actelion.com approximately 60 minutes after the call has ended.
Press release.PDF:
http://hugin.info/131801/R/1975282/722857.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via GlobeNewswire
[HUG#1975282]
Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Datum: 22.12.2015 - 07:37 Uhr
Sprache: Deutsch
News-ID 1302814
Anzahl Zeichen: 2075
Kontakt-Informationen:
Stadt:
Allschwil
Kategorie:
Wirtschaft (allg.)
Diese Pressemitteilung wurde bisher 451 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion to discuss US FDA approval of Uptravi (selexipag) for the treatment of pulmonary arterial hypertension"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
